Fenebrutinib, a Bruton’s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways

Abstract Background Bruton’s tyrosine kinase (BTK) is an intracellular signaling enzyme that regulates B-lymphocyte and myeloid cell functions. Due to its involvement in both innate and adaptive immune compartments, BTK inhibitors have emerged as a therapeutic option in autoimmune disorders such as...

Descripció completa

Dades bibliogràfiques

Autors principals:	Julie Langlois, Simona Lange, Martin Ebeling, Will Macnair, Roland Schmucki, Cenxiao Li, Jonathan DeGeer, Tania J. J. Sudharshan, V. Wee Yong, Yun-An Shen, Christopher Harp, Ludovic Collin, James Keaney
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-10-01
Col·lecció:	Journal of Neuroinflammation
Matèries:	Multiple sclerosis Fenebrutinib BTK Neuroinflammation Microglia Organoids
Accés en línia:	https://doi.org/10.1186/s12974-024-03267-5
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!